Scarica l'app Stockscreener
36.26
1.94%
0.69
Precedente Chiudi:
$35.57
Aprire:
$35
Volume 24 ore:
398.21K
Relative Volume:
0.74
Capitalizzazione di mercato:
$1.74B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+11.47%
1M Prestazione:
+22.83%
6M Prestazione:
+244.68%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$34.44
$36.99
Intervallo di 1 settimana:
$31.47
$37.23
Portata 52W:
$6.71
$37.23
Maze Therapeutics Inc Stock (MAZE) Company Profile
Nome
Maze Therapeutics Inc
Settore
Industria
Telefono
(650) 850-5070
Indirizzo
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Confronta MAZE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
36.26 | 1.71B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-14 | Iniziato | Raymond James | Outperform |
| 2025-09-02 | Iniziato | BTIG Research | Buy |
| 2025-07-23 | Iniziato | H.C. Wainwright | Buy |
| 2025-07-08 | Iniziato | Wedbush | Outperform |
Maze Therapeutics Inc Borsa (MAZE) Ultime notizie
Will Maze Therapeutics Inc. stock sustain high P E ratiosTrade Entry Report & Weekly Setup with ROI Potential - newser.com
Will Maze Therapeutics Inc. stock benefit from commodity pricesAnalyst Upgrade & Verified Swing Trading Watchlists - newser.com
Price action breakdown for Maze Therapeutics Inc.2025 Stock Rankings & High Yield Equity Trading Tips - newser.com
Is Maze Therapeutics Inc. stock recession proofJuly 2025 PostEarnings & Safe Capital Investment Plans - newser.com
Maze Therapeutics Inc. stock momentum explainedJuly 2025 Sector Moves & Safe Swing Trade Setups - newser.com
Heatmap analysis for Maze Therapeutics Inc. and competitorsLong Setup & Consistent Income Trade Ideas - newser.com
Will Maze Therapeutics Inc. stock deliver consistent dividendsStock Surge & AI Based Buy and Sell Signals - newser.com
Applying chart zones and confluence areas to Maze Therapeutics Inc.Entry Point & Long-Term Safe Return Strategies - newser.com
Can you recover from losses in Maze Therapeutics Inc.Quarterly Profit Report & Free Safe Capital Growth Stock Tips - newser.com
Pattern recognition hints at Maze Therapeutics Inc. upsideJuly 2025 Trends & Safe Investment Capital Preservation Plans - newser.com
Is Maze Therapeutics Inc. stock attractive for long term wealth buildingJuly 2025 Price Swings & Breakout Confirmation Alerts - newser.com
Will Maze Therapeutics Inc. outperform the marketOptions Play & High Win Rate Trade Tips - newser.com
How institutional buying supports Maze Therapeutics Inc. stock2025 Price Targets & Fast Entry High Yield Stock Tips - newser.com
Is Maze Therapeutics Inc. stock oversold or undervaluedJuly 2025 Setups & Weekly Watchlist for Hot Stocks - newser.com
Regression analysis insights on Maze Therapeutics Inc. performanceMarket Risk Report & Safe Entry Momentum Tips - newser.com
Analyzing Maze Therapeutics Inc. with multi timeframe charts2025 Technical Overview & Low Volatility Stock Recommendations - newser.com
Raymond James initiates Maze Therapeutics stock with Outperform rating By Investing.com - Investing.com Canada
Maze Therapeutics Inc Azioni (MAZE) Dati Finanziari
Non sono disponibili dati finanziari per Maze Therapeutics Inc (MAZE). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
1.38%
1.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):